The USA-based company's product candidates, Rhopressa (netarsudil ophthalmic solution) and Roclatan (netarsudil/latanoprost ophthalmic solution), are once-daily eye drops that, if approved, will provide eye-care professionals with the first novel intraocular pressure-lowering mechanisms of action to treat glaucoma in nearly 20 years.

This approval could come from the US Food and Drug Administration in the final quarter of 2017 for Rhopressa.